Patents by Inventor Antonio Ricci

Antonio Ricci has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Isoindolinone and indazole compounds for the degradation of EGFR
    Patent number: 11673902
    Abstract: The invention provides compounds that degrade the epidermal growth factor receptor (EGFR) including mutant forms via the ubiquitination of the EGFR protein and subsequent proteasomal degradation. The compounds are useful for the treatment of various cancers.
    Type: Grant
    Filed: June 17, 2022
    Date of Patent: June 13, 2023
    Assignee: C4 Therapeutics, Inc.
    Inventors: Christopher G. Nasveschuk, Martin Duplessis, Jae Young Ahn, Alexander W. Hird, Ryan E. Michael, Kiel Lazarski, Yanke Liang, Georg Jaeschke, Antonio Ricci, Annick Goergler, Daniel Rueher
  • ISOINDOLINONE AND INDAZOLE COMPOUNDS FOR THE DEGRADATION OF EGFR
    Publication number: 20230110648
    Abstract: The invention provides compounds that degrade the epidermal growth factor receptor (EGFR) including mutant forms via the ubiquitination of the EGFR protein and subsequent proteasomal degradation. The compounds are useful for the treatment of various cancers.
    Type: Application
    Filed: June 17, 2022
    Publication date: April 13, 2023
    Applicant: C4 Therapeutics, Inc.
    Inventors: Christopher G. Nasveschuk, Martin Duplessis, Jae Young Ahn, Alexander W. Hird, Ryan E. Michael, Kiel Lazarski, Yanke Liang, Georg Jaeschke, Antonio Ricci, Annick Goergler, Daniel Rueher
  • EGFR INHIBITORS FOR THE TREATMENT OF CANCER
    Publication number: 20230054473
    Abstract: The application relates to (106) specific heterocyclic compounds comprising a thiazole ring, an indazol and a 6,7-dihydro-5H-pyrrolo[1,2-c]imidazole system, to pharmaceutical compositions containing them and their medical use. The compounds are described as selective allosteric inhibitors of T790M/L858R, T790M/L858R/C797S, L858R, L858R/C797S containing EGFR mutants and thus useful for the treatment of cancer, in particular non-small cell lung cancer.
    Type: Application
    Filed: June 19, 2020
    Publication date: February 23, 2023
    Applicant: Hoffmann-La Roche Inc.
    Inventors: Cosimo DOLENTE, Annick GOERGLER, David HEWINGS, Georg JAESCHKE, Bernd KUHN, Yvonne Alice NAGEL, Christa Ulrike OBST-SANDER, Antonio RICCI, Daniel RUEHER, Sandra STEINER
  • EGFR INHIBITORS
    Publication number: 20230057891
    Abstract: The application provides a compound having the general formula (I) wherein R1, R2, R3 and R4 are as defined in the description and in the claims. The compound of formula (I) can be used as a medicament.
    Type: Application
    Filed: December 18, 2020
    Publication date: February 23, 2023
    Applicant: Hoffmann-La Roche Inc.
    Inventors: David Stephen HEWINGS, Georg JAESCHKE, Bernd KUHN, Yvonne Alice NAGEL, Antonio RICCI
  • EGFR INHIBITORS
    Publication number: 20230034696
    Abstract: The application provides a compound having the general formula (I) or a pharmaceutically acceptable salt thereof, compositions including the compound and methods of using the compound. The compound of formula (I) can be used as a medicament.
    Type: Application
    Filed: December 18, 2020
    Publication date: February 2, 2023
    Applicant: Hoffmann-La Roche Inc.
    Inventors: Georg JAESCHKE, Bernd KUHN, Yvonne Alice NAGEL, Antonio RICCI
  • Process for the preparation of high purity glucagon
    Patent number: 11566058
    Abstract: The present invention provides an improved process for the preparation of high purity glucagon comprising the use of Xmb-protected amino acids, wherein may Xmb include, e.g., 2,4,6-trimethoxybenzyl, 2,4-dimethoxybenzyl, or 2-hydroxy-4-methoxybenzyl. The process also comprises the use of building blocks such as pseudoprolines to avoid aggregation and obtain the product in high yield and purity.
    Type: Grant
    Filed: June 18, 2020
    Date of Patent: January 31, 2023
    Assignee: Fresenius Kabl iPSUM S.R.L.
    Inventors: Andrea Orlandin, Antonio Ricci, Walter Cabri, Steve McIntyre, Alex Saunders
  • PROCESS FOR THE MANUFACTURE OF GLUCAGON
    Publication number: 20220324936
    Abstract: The present invention provides an improved process for the preparation of glucagon, comprising the coupling of an N-terminal tetramer fragment with a C-terminal peptide, comprising at least one pseudoproline. The process is very efficient in avoiding aggregation and obtaining the desired product in high yield and purity.
    Type: Application
    Filed: June 18, 2020
    Publication date: October 13, 2022
    Applicant: FRESENIUS KABI IPSUM S.R.L.
    Inventors: Andrea ORLANDIN, Antonio RICCI, Walter CABRI
  • EGFR INHIBITORS FOR THE TREATMENT OF CANCER
    Publication number: 20220315593
    Abstract: The application relates to 6 specific heterocyclic compounds, pharmaceutical compositions containing them and their medical use. The compounds are described as selective allosteric inhibitors of T790M/L858R, T790M/L858R/C797S, L858R, L858R/C797S containing EGFR mutants and thus useful for the treatment of cancer, in particular non-small cell lung cancer.
    Type: Application
    Filed: June 19, 2020
    Publication date: October 6, 2022
    Applicant: Hoffmann-La Roche Inc.
    Inventors: Cosimo DOLENTE, Annick GOERGLER, David HEWINGS, Georg JAESCHKE, Bernd KUHN, Yvonne Alice NAGEL, Christa Ulrike OBST-SANDER, Antonio RICCI, Daniel RUEHER, Sandra STEINER
  • NEW EGFR INHIBITORS
    Publication number: 20220315591
    Abstract: The invention provides novel compounds as described herein, compositions including the compounds and methods of using the compounds.
    Type: Application
    Filed: June 19, 2020
    Publication date: October 6, 2022
    Applicant: Hoffmann-La Roche Inc.
    Inventors: Cosimo DOLENTE, Annick GOERGLER, David Stephen HEWINGS, Georg JAESCHKE, Bernd KUHN, Yvonne Alice NAGEL, Roger David NORCROSS, Christa Ulrike OBST-SANDER, Antonio RICCI, Daniel RUEHER, Sandra STEINER
  • EGFR INHIBITOR FOR THE TREATMENT OF CANCER
    Publication number: 20220315592
    Abstract: The application relates to a compound of formula (I) containing a thiazole ring, an indazol ring and a 6,7-dihydro-5H-pyrrolo[1,2-c]imidazole ring system, to pharmaceutical compositions containing it and its medical use. The compounds are described as selective allosteric inhibitors of T790M/L858R, T790M/L858R/C797S, L858R, L858R/C797S containing EGFR mutants and thus useful for the treatment of cancer, in particular non-small cell lung cancer.
    Type: Application
    Filed: June 19, 2020
    Publication date: October 6, 2022
    Applicant: Hoffmann-La Roche Inc.
    Inventors: Cosimo DOLENTE, Annick GOERGLER, David HEWINGS, Georg JAESCHKE, Bernd KUHN, Yvonne Alice NAGEL, Christa Ulrike OBST-SANDER, Antonio RICCI, Daniel RUEHER, Sandra STEINER
  • NEW EGFR INHIBITORS
    Publication number: 20220315577
    Abstract: The invention provides novel compounds having the general formula (I) wherein R1, R3, R4, R5 and R10 are as described herein, compositions including the compounds and methods of using the compounds.
    Type: Application
    Filed: June 19, 2020
    Publication date: October 6, 2022
    Applicant: Hoffmann-La Roche Inc.
    Inventors: Georg JAESCHKE, Bernd KUHN, Yvonne Alice NAGEL, Antonio RICCI, Daniel RUEHER, Sandra STEINER
  • Process for the manufacture of GLP-1 analogues
    Patent number: 11396533
    Abstract: The present invention provides a process for the manufacture of GLP-1 analogues with high yield and purity by fragment condensation on the solid phase. In particular, it describes a convergent synthesis by condensation of a C-terminal pseudoproline fragment A with a fragment B bound to a solid support, followed by deprotection and cleavage from the support and final purification to yield the desired peptide. The invention further provides intermediates useful in the manufacturing process.
    Type: Grant
    Filed: October 9, 2019
    Date of Patent: July 26, 2022
    Assignee: FRESENIUS KABI IPSUM S.R.L.
    Inventors: Giuseppina Maria Incisivo, Andrea Orlandin, Antonio Ricci, Ivan Guryanov, Walter Cabri
  • AMINO DEPROTECTION USING 3-(DIETHYLAMINO)PROPYLAMINE
    Publication number: 20220185842
    Abstract: The invention provides a method for the cleavage of Fmoc group characterized by using a solution comprising 3-(diethylamino)propylamine. In particular, it provides a method for the preparation of peptides in solid phase wherein Fmoc protected amino acids are used and the Fmoc group is cleaved by a solution comprising 3-(diethylamino)propylamine.
    Type: Application
    Filed: December 9, 2021
    Publication date: June 16, 2022
    Applicants: Alma Mater Studiorum - Università di Bologna, FRESENIUS KABI IPSUM S.R.L.
    Inventors: Giulia MARTELLI, Paolo CANTELMI, Alessandra TOLOMELLI, Chiara PALLADINO, Lucia FERRAZZANO, Walter CABRI, Marco MACIS, Angelo VIOLA, Antonio RICCI
  • PROCESS FOR THE PREPARATION OF DEGARELIX
    Publication number: 20220177521
    Abstract: The present invention provides a manufacturing process for the preparation of degarelix by using Fmoc protected amino acids as building blocks, wherein the Fmoc group is cleaved by treatment with tert-butylamine.
    Type: Application
    Filed: March 5, 2020
    Publication date: June 9, 2022
    Inventors: Walter Cabri, Andrea Orlandin, Angelo Viola, Antonio Ricci, Ivan Guryanov
  • THERAPEUTIC EGFR INHIBITORS
    Publication number: 20220135571
    Abstract: The invention provides novel compounds as described herein, compositions including the compounds and methods of using the compounds.
    Type: Application
    Filed: December 21, 2021
    Publication date: May 5, 2022
    Applicant: Hoffmann-La Roche Inc.
    Inventors: Cosimo Dolente, Annick Goergler, Georg Jaeschke, Bernd Kuhn, Christa Ulrike Obst-Sander, Antonio Ricci, Daniel Rueher, Sandra Steiner, David Hewings, Yvonne Alice Nagel
  • ETHYNYL DERIVATIVES
    Publication number: 20220127275
    Abstract: The present invention relates to compounds that may be used in the treatment of Parkinson's disease, anxiety, emesis, obsessive compulsive disorder, autism, neuroprotection, cancer, depression or diabetes type 2.
    Type: Application
    Filed: January 4, 2022
    Publication date: April 28, 2022
    Applicant: Hoffmann-La Roche Inc.
    Inventors: Barbara BIEMANS, Georg JAESCHKE, Antonio RICCI, Daniel RUEHER, Fionn O'HARA
  • EGFR INHIBITOR FOR MEDICAL USE
    Publication number: 20220112199
    Abstract: The invention provides novel a compound having the general formula (I) as described herein, compositions including the compound and methods of using the compound.
    Type: Application
    Filed: December 21, 2021
    Publication date: April 14, 2022
    Inventors: Cosimo Dolente, Annick Goergler, David Hewings, Georg Jaeschke, Bernd Kuhn, Yvonne Alice Nagel, Roger David Norcross, Christa Ulrike Obst-Sander, Antonio Ricci, Daniel Rueher, Sandra Steiner
  • PROCESS FOR THE MANUFACTURE OF GLP-1 ANALOGUES
    Publication number: 20220041680
    Abstract: The present invention provides a process for the manufacture of GLP-1 analogues with high yield and purity by fragment condensation on the solid phase. In particular, it describes a convergent synthesis by condensation of a C-terminal pseudoproline fragment A with a fragment B bound to a solid support, followed by deprotection and cleavage from the support and final purification to yield the desired peptide. The invention further provides intermediates useful in the manufacturing process.
    Type: Application
    Filed: October 9, 2019
    Publication date: February 10, 2022
    Applicant: FRESENIUS KABI IPSUM S.R.L.
    Inventors: Giuseppina Maria INCISIVO, Andrea ORLANDIN, Antonio RICCI, Ivan GURYANOV, Walter CABRI
  • Ethynyl derivatives
    Patent number: 11242349
    Abstract: The present invention relates to compounds that may be used in the treatment of Parkinson's disease, anxiety, emesis, obsessive compulsive disorder, autism, neuroprotection, cancer, depression or diabetes type 2.
    Type: Grant
    Filed: May 1, 2020
    Date of Patent: February 8, 2022
    Assignee: Hoffmann-La Roche Inc.
    Inventors: Barbara Biemans, Georg Jaeschke, Antonio Ricci, Daniel Rueher, Fionn O'Hara
  • PROCESS FOR THE MANUFACTURE OF DEGARELIX AND ITS INTERMEDIATES
    Publication number: 20220033443
    Abstract: The present invention provides a manufacturing process for preparing a peptide, preferably a decapeptide, such as degarelix, by incorporating p-nitro-phenylalanin in the amino acid sequence preferably during stepwise solid phase synthesis, and converting these into the required amino acids Aph(Hor) and/or D-Aph(Cbm), preferably while attached to a solid phase. The invention further provides intermediates useful in the manufacturing process.
    Type: Application
    Filed: October 15, 2021
    Publication date: February 3, 2022
    Applicant: Fresenius Kabi iPSUM S.r.l
    Inventors: Antonio RICCI, Jacopo ZANON, Walter CABRI, Ivan GURYANOV, Andrea ORLANDIN, Barbara BIONDI, Fernando FORMAGGIO, Dario VISENTINI